Continuous synthesis of ginkgolide B derivatives in a micro-flow system

Application of Microfluidics in Process Intensification

Is it possible to miniaturize a chemical plant? Some strategies, such as the process intensification, sustain that the advancements in equipment and production techniques could substantially decrease the equipment size/production capacity ratio, energy consumption and waste generation, resulting in more economic and sustainable operations and consequently reducing the chemical plant size. However, large reductions of equipment volume represent a major challenge for the conventional technologies. In this context, Microfluidics represents a promising technology in the field of system miniaturization. Accordingly, the present research evaluated the concept of process intensification and its relationship with Microfluidics. Initially, the definition and the classification of process intensification were described, following by the explanation of the Microfluidics, highlighting scale-up strategies and examples using miniaturized systems. Afterward, a methodology for miniaturized devices development for process intensification using numerical simulations was shown. Finally, the conclusions are exposed.

Continuous flow chemistry: where are we now? Recent applications, challenges and limitations

A general outlook of the changing face of chemical synthesis is provided in this article through recent applications of continuous flow processing in both industry and academia. The benefits, major challenges and limitations associated with the use of this mode of processing are also given due attention as an attempt to put into perspective the current position of continuous flow processing, either as an alternative or potential combinatory technology for batch processing.

An embryo-fetal development toxicity study with dimethylaminoethyl ginkgolide B in rats and rabbits

Ginkgo biloba (a herbal product) has long been used in traditional Chinese medicine to treat cerebrovascular and cardiovascular diseases. Ginkgolide B is one of the important pharmacologically active components of Ginkgo biloba. Dimethylaminoethyl ginkgolide B (a novel ginkgolide B derivative) has been developed to overcome the poor water-solubility of natural drugs and to achieve higher bioavailability. This study investigated the potential effects of dimethylaminoethyl ginkgolide B on pregnant dams and embryo-fetal development in Sprague-Dawley rats and New Zealand white rabbits following maternal exposure on gestational day (GD) 6-15 and GD 6-18, respectively. Dimethylaminoethyl ginkgolide B was administered by intravenous injection to pregnant rats (0, 10, 30 and 100 mg kg-1 d-1) and rabbits (0, 6, 18 and 60 mg kg-1 d-1). Maternal toxicity signs, such as lower maternal body weight gain and food consumption, were observed at 100 mg kg-1 d-1 in rats and 60 mg kg-1 d-1 in rabbits. The developmental toxic effects included a decrease in fetal and placental weights, increased incidences of skeletal variations and delay in fetal ossification. Fetal growth and development were affected by dimethylaminoethyl ginkgolide B in the high-dose group in rabbits. The no-observed-adverse-effect level of dimethylaminoethyl ginkgolide B is considered to be 30 mg kg-1 d-1 for rats and 18 mg kg-1 d-1 for rabbits.